Mergers & Acquisitions
By The Online Investor Staff, updated Sun., Jan. 29, 6:29 PM
| This Slide: #60 of 100 |
Slide #60. Elicio Therapeutics — Angion Biomedica Corp
Acquirer:
Elicio Therapeutics
Acquiree:
Angion Biomedica Corp (NASDAQ:ANGN)
Details:
Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp (NASDAQ:ANGN) under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. The combined company will continue under the Elicio Therapeutics name and will focus on advancing Elicio's proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
Open the ANGN Page at The Online Investor »
|
|||||||||||||||||||||
Open the ANGN Page at The Online Investor (in a new window) »
 Free ANGN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Hold (2.00 out of 4) 0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
